Shattuck Labs (STTK) AI Stock Analysis

• Market Cap: $51.73M
• Dividend Yield: N/A
• Average Volume (3M): 245.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.85
• Revenue Growth: 245.26%
• EPS Growth: 27.54%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -1.49
• Shares Outstanding: 47,899,240
• 10 Day Avg. Volume: 133,544
• 30 Day Avg. Volume: 245,739
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.16
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.41
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $4.00
• Price Target Upside: 270.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

Shattuck Labs faces significant profitability and cash flow challenges despite strong revenue growth, with a low leverage balance sheet as a relative strength. Technical analysis indicates bearish momentum, and valuation metrics suggest potential undervaluation contingent on future profitability improvements.

Positive Factors

Clinical Development

Shattuck announced a promising preclinical profile for its lead asset, SL-325, aimed at treating inflammatory bowel disease.

Financial Stability

The company has $73 million in cash, which provides runway for all ongoing operations into 2027.

Market Opportunity

Shattuck's pivot into the inflammatory bowel disease market is seen as an underappreciated opportunity, with the lead program SL-325 offering a first-in-class approach that could improve upon existing clinically-validated programs.

Negative Factors

Analyst Rating

Analyst maintains a Hold Rating given the early stage of the company pipeline at this time and a lack of near-term value drivers.

Earnings

Shattuck posted a full-year EPS of ($1.49), which was below consensus estimates.

Shattuck Labs Business Overview & Revenue Model

Company Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

How the Company Makes Money

Shattuck Labs generates revenue primarily through strategic partnerships and collaborations with other pharmaceutical and biotechnology companies. These partnerships often involve the co-development and commercialization of its proprietary ARC platform-based therapies. Additionally, the company may earn revenue from milestone payments and royalties associated with the successful advancement and commercialization of its therapeutic candidates. As a clinical-stage company, Shattuck Labs may also receive funding from grants or research collaborations to support its research and development activities.

Shattuck Labs Financial Statement Overview

Summary

Shattuck Labs shows strong revenue growth but remains unprofitable with significant operational challenges, including negative EBIT and EBITDA. The balance sheet is stable with low leverage, but ongoing losses and negative cash flows necessitate strategic adjustments.

Income Statement

Shattuck Labs has shown significant revenue growth from the previous year, with a Revenue Growth Rate of approximately 245.32%. However, the company remains unprofitable with a negative Net Profit Margin of -131.82% and a negative EBIT Margin. The company has consistently generated negative EBIT and EBITDA over the years, indicating ongoing operational challenges.

Balance Sheet

The balance sheet shows a stable equity position with a Debt-to-Equity Ratio of 0.03, indicating low leverage. The Equity Ratio of 87.47% suggests a strong equity base relative to total assets. However, the company has a history of net losses, which could impact future equity stability.

Cash Flow

Free cash flow remains negative, though there’s a slight improvement in free cash flow growth rate compared to previous years. The Operating Cash Flow to Net Income Ratio is negative, reflecting cash flow issues. The company's cash position has been supported by financing activities, highlighting reliance on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
5.72M	1.66M	652.00K	30.02M	9.93M
	Gross Profit
5.72M	-2.38M	-2.72M	28.64M	-27.55M
	EBIT
-80.57M	-91.96M	-103.33M	-45.27M	-36.93M
	EBITDA
-80.57M	-87.61M	-100.26M	-43.89M	-36.31M
	Net Income Common Stockholders
-75.41M	-87.30M	-100.56M	-44.35M	-35.44M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
57.39M	130.63M	161.28M	268.80M	335.45M
	Total Assets
91.05M	159.56M	205.32M	298.58M	348.99M
	Total Debt
2.51M	4.20M	4.20M	0.00	0.00
	Net Debt
-54.88M	-121.42M	-43.18M	-92.27M	-157.90M
	Total Liabilities
11.42M	14.86M	29.17M	26.80M	39.13M
	Stockholders Equity
79.63M	144.71M	176.16M	271.79M	309.86M
Cash Flow		Free Cash Flow
-60.57M	-81.64M	-106.11M	-65.04M	-34.39M
	Operating Cash Flow
-60.52M	-81.23M	-94.50M	-57.12M	-33.66M
	Investing Cash Flow
-8.51M	110.86M	49.44M	-10.44M	-146.32M
	Financing Cash Flow
787.00K	48.62M	171.00K	1.93M	330.87M

Shattuck Labs Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Neutral. The current price of 1.08 is above the 20-day moving average (MA) of 0.88, below the 50-day MA of 1.09, and below the 200-day MA of 1.86, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 56.75 is Neutral, neither overbought nor oversold. The STOCH value of 83.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for STTK.

Shattuck Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	62 Neutral	$60.66M	1.93	-58.97%	―	36.45%	―
DTIL	56 Neutral	$60.35M	3.02	19.05%	―	40.98%	―
Sector *	52 Neutral	$5.28B	3.75	-42.72%	2.86%	17.70%	2.03%
KRON	46 Neutral	$43.56M	―	-69.80%	―	56.62%	26.48%
GANX	46 Neutral	$62.67M	―	-204.95%	―	-100.00%	44.28%
PEPG	42 Neutral	$51.37M	―	-79.26%	―	―	14.06%
STTK	39 Underperform	$51.73M	―	-67.23%	―	245.26%	27.54%